



# 11th North of England Breast Cancer Symposium

[www.neonc.org.uk](http://www.neonc.org.uk)

## Dr Penny Moyle



Dr Moyle is a Consultant Radiologist at Cambridge University Hospital with a specialist interest in Breast Imaging. Dr Moyle has been Clinical Lead for the Cambridge Breast Unit since 2014 and was Director of Cambridge & Huntingdon Breast Screening 2013-2019.

Currently involved in research projects which include contrast enhanced mammography, multicentre interval cancer data, high risk cancer data and automated breast ultrasound. Dr Moyle is involved in service improvement audits within our unit and writes modules for the RCR Radiology – Integrated Training Initiative (R-ITI) and the National Breast Imaging Academy Modules.

Dr Moyle has spoken at national and international conferences on topics such as interval cancers, performance management, Duty of Candour, contrast enhanced mammography and oncoplastic breast surgery for radiologists.

## Professor Robert Coleman MBBS, MD, FRCP, FRCPE



**Professor Robert (Rob) Coleman** is Emeritus Professor of Medical Oncology in the Department of Oncology and Metabolism at the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network.

Despite recently retiring from his formal position at the university, he remains research active and still leads a number of national and international clinical trials. Since 2014 he has been a part-time Medical Director for the global independent medical education provider, prIME Oncology™, developing and delivering both live and on-line educational activities for oncologists and other providers of cancer care.

Professor Coleman is a past-president of the Cancer and Bone Society and the founding editor of “Journal of Bone Oncology”. He has published nearly 450 peer reviewed manuscripts and numerous book chapters. He is also a trustee and deputy chair of the board at St Luke’s Hospice in Sheffield and a trustee for the Weston Park Cancer Charity.

## Mr Henry Cain



Henry Cain qualified in 2001 from Leicester and returned to the North of England to complete his surgical training. Following the award of MD in breast cancer signalling pathways and higher surgical training he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow. He was appointed a Consultant Oncoplastic surgeon at the Royal Victoria Infirmary Newcastle upon Tyne in 2013. Henry Cain maintains numerous research activities along with a commitment in teaching advanced oncoplastic breast surgery. He is a member of the Faculty for the ABS advanced breast disease course and organises the ABS annual Trainees Meeting. He is a faculty member for the National Breast TIG fellow’s course. Clinically he has been one of the lead surgeons in the introduction of Radioactive Seed Localisation of impalpable breast cancer to the UK.



## 11th North of England Breast Cancer Symposium

[www.neonc.org.uk](http://www.neonc.org.uk)

### Dr Andreas Makris



Medical undergraduate training at Oriel College, Oxford and Sheffield University Medical School. Trained in Clinical Oncology at Weston Park Hospital, Sheffield and the Royal Marsden Hospital, London. Appointed Consultant in Clinical Oncology at the Mount Vernon Cancer Centre, in 1997.

Specializes in the treatment of breast cancer and has published over 100 papers related to breast cancer research. He is co-Chief Investigator of the OPTIMA Trial which is investigating whether adjuvant chemotherapy can be avoided in women with high-risk early breast cancer. He is the Chief Investigator of the RESPECT trial that aims to establish the role of Whole-Body MRI in the evaluation of bone metastases in advanced breast cancer.

He is the co-Chairman of the UK Breast Cancer Group and is a member of the Executive Committee of the UK Inter-disciplinary Breast Cancer Meeting.

### Prof Andrew Wardley



Professor Andrew Wardley has been Consultant Medical Oncologist for breast cancer at The Christie since 2001. He formed and led the Christie Hospital Breast Cancer Research Team to become the most successful breast cancer research team in the UK. He has an international reputation for breast cancer research. In 2005 he was one of the founding members of Manchester Breast Centre (MBC).

Professor Wardley has been Clinical Director of the Early Phase Trials Unit since December 2011 and led the successful bid for £4.5M funding from the National Institute for Health Research for clinical research facilities. This is one of the largest Early Phase Trials Units in the world. The facility supports and promotes the rapid development of new targeted therapies and innovative treatments in cancer care, and the advancement of personalised medicine.

Professor Wardley Clinical Lead for Systemic Anti-Cancer Therapy since February 2011 and Greater Manchester Director since 2015. His vision is of equitable access to cancer clinical trials for all patients in Greater Manchester. He is committed to excellence through personal involvement in direct patient care, training, audit, research and effecting change.

### Dr Marina Parton



Dr Marina Parton is a Medical Oncologist in Breast Cancer at The Royal Marsden and Kingston Hospital. Appointed to The Royal Marsden Consultant Body in 2009, she received her oncology training at The Royal Marsden and carried out her research in neoadjuvant therapy in breast cancer as part of a MD at The Institute of Cancer Research with Professors Dowsett and Smith.

Dr Parton is Lead Cancer Clinician in The Royal Marsden's first satellite chemotherapy unit, a joint venture with Kingston Hospital and Macmillan Cancer Support. She has published in breast cancer research and is principle investigator in a number of clinical trials at The Royal Marsden and Kingston Hospital. She is Chair of the Acute Oncology Group at The Royal Marsden, part of the Breast Pathway Group at London Cancer Alliance (LCA) and co-chair of the LCA Chemotherapy Closer to Home Group. She is committed to developing the cancer services at The Royal Marsden and Kingston.

Dr Parton specialises in treating early and secondary breast cancer, breast cancer survivorship and breast cancer therapy effects.



## Dr Elena Provenzano



Dr Elena Provenzano is Lead Breast Histopathologist for the Cambridge Breast Unit at Addenbrooke's Hospital. She completed her pathology training in Melbourne, Australia in 2005, before moving to the UK to undertake a breast fellowship with Prof Sarah Pinder. Her current role combines clinical work and research, with key interests in the molecular taxonomy of breast cancer and assessment of tumour response to neoadjuvant therapy. She is a co-investigator in several breast cancer trials that include ARTemis, PARTNER, PRIMETIME and Neo-RT clinical trials. She participated as a member of the BIG/NABCG Residual Disease Working Group composing guidelines for assessment of breast cancer post neoadjuvant chemotherapy, and is a member of UK National Coordinating Committee for Breast Pathology.


## Prof Ian Kunkler



Professor Ian Kunkler ([www.iankunkler.org.uk](http://www.iankunkler.org.uk)) is Consultant and Honorary Professor in Clinical Oncology at the Edinburgh Cancer Centre, University of Edinburgh. He qualified in Medicine at Cambridge University and St Bartholomew's Hospital in London. After experience in general medicine in Nottingham, he moved to Edinburgh and trained in Clinical Oncology. He spent a year as a French Government and EEC research fellow at Institut Gustave Roussy in Paris. He was subsequently appointed consultant in Clinical Oncology in Sheffield in 1988. He returned to Edinburgh in 1992 specialising in the non surgical treatment of breast cancer.

His research interests are in adjuvant trials of radiotherapy for older patients with breast cancer and the development of biosensors to optimise radiotherapy for solid hypoxic tumours. He is Chief Investigator of the BIG 2-04 MRC/EORTC SUPREMO trial, the CSO funded PRIME 2 trial, UK lead for the Breast Cancer Now funded BIG 3-07 DCIS boost and co-PI of the EPSRC funded IMPACT project ([www.impact.eng.ed.ac.uk](http://www.impact.eng.ed.ac.uk)) on implantable microsystems for personalised anti-cancer therapy. He has edited two editions of Walter and Miller's Textbook of Radiotherapy and published over 150 articles. He is a past President of the British Oncological Association.

## Dr Maria Vidal Losada



Maria Vidal, MD, PhD

Medical oncologist at Hospital Clinic, Barcelona. IDIBAPS, Barcelona. Spain.

Dr Maria Vidal received her degree in Medicine from the prestigious University of Barcelona in 2004. After completing her residency as a Medical Oncologist, she pursued a fellowship in the Breast and Melanoma Unit at Vall d'Hebron University Hospital in Barcelona. Whilst there, she actively participated in more than 50 trials concerning breast cancer from phase I to III. In 2012, she acted as attending physician in her steadfast commitment to quality patient care and treatment in the same unit. Additionally, she collaborated with both various research programmes in Vall d'Hebron Institute of Oncology, as well as the Translational Genomics group—led by renowned breast cancer investigator Dr Prat—to develop her doctoral thesis in “Genomic classification of the fibroepithelial tumours of the mammary gland”.

Since 2016, she has been serving as a medical oncologist in the Breast Cancer Unit and Translational Genomics and Targeted Therapeutics at Hospital Clinic in Barcelona, under the supervision of Dr Prat.

Dr Maria Vidal is a leading expert in breast cancer, with more than 30 publications in the field.

Her current primary line of research concerns breast cancer genomics. Dr Maria Vidal is a recognised member of the SEOM and SOLTI groups in Spain.



## 11th North of England Breast Cancer Symposium

[www.neonc.org.uk](http://www.neonc.org.uk)

### Prof David Dodwell



David Dodwell is a senior clinical research fellow. He now works in Oxford after 20+ years as an NHS consultant in Leeds and has a major clinical and research interest in breast cancer. He works full time in the Nuffield Department of Population Health, Oxford University. He is a co-lead in EBCTCG and is involved in other epidemiological work programmes and major national audits.

### Dr Neelam Siddiqui



Dr Neelam Siddiqui is a consultant medical oncologist at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMH) Lahore, Pakistan. She is also program director of medical oncology fellowship program at the hospital. She has special interest in the management of breast and ovarian cancer, and also in the management of Lympho-proliferative disorders. She is also experienced in the management of cancer patients with high dose chemotherapy and stem cell rescue.

Dr Siddiqui earned MBBS from Fatima Jinnah Medical College Lahore (Pakistan) in 1984. She was trained in medical oncology at New Castle where she received MRCP (UK) and CCST (Medical Oncology UK). Later she has moved to Kingdom of Saudi Arabia where she worked in the country's top university hospitals and gained experience in the management of patients with haematological tumours, solid cancers and stem cell therapy. She remained part of university faculty and also involved in teaching and different research projects.

She joined Shaukat Khanum Memorial Hospital in 2005. With College of Physicians and Surgeons Pakistan (CPSP), she designed post-graduate training program in medical oncology at SKMH. She has trained dozens of medical oncologists over years and earned post-graduate certification (FCPS). She is also examiner for medical oncology board (FCPS) in Pakistan. Her research in both solid and haematological cancers is published in multiple peer reviewed medical journals.